Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Disability and Rehabilitation
|
October 29, 2000
Accelerating the return to work (RTW) chances of coronary heart disease (CHD) patients: part 1--development and validation of a training programme
A Mital, D E Shrey, M Govindaraju, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography
|
November 1, 1989
Regional wall motion index for infarct and noninfarct regions after reperfusion in acute myocardial infarction: comparison with global wall motion index
P D Bourdillon, T M Broderick, S G Sawada, et al.
The American Journal of Cardiology
|
March 15, 1989
Early recovery of regional left ventricular function after reperfusion in acute myocardial infarction assessed by serial two-dimensional echocardiography
P D Bourdillon, T M Broderick, E S Williams, et al.
Journal of Thrombosis and Thrombolysis
|
June 22, 1999
Efficacy of abciximab induced platelet blockade using a rapid point of care assay
D J Kereiakes, M Mueller, W Howard, et al.
The American Journal of Cardiology
|
August 3, 2000
Usefulness of stent length in predicting in-stent restenosis (the MULTI-LINK stent trials)
D Kereiakes, T J Linnemeier, D S Baim, et al.
The American Journal of Cardiology
|
September 1, 1999
Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
D J Kereiakes, T M Broderick, E M Roth, et al.
Circulation
|
August 19, 1997
Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment
D J Kereiakes, N Kleiman, J J Ferguson, et al.
Journal of Thrombosis and Thrombolysis
|
December 30, 1999
High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists
D J Kereiakes, T M Broderick, E M Roth, et al.
American Heart Journal
|
March 7, 2001
Dalteparin in combination with abciximab during percutaneous coronary intervention
D J Kereiakes, N S Kleiman, E Fry, et al.
The Journal of Invasive Cardiology
|
April 14, 2000
Combination enoxaparin-abciximab therapy during coronary intervention: the next standard of care?
D A Tramuta, D J Kereiakes, E J Dippel, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Disability and Rehabilitation
|
October 29, 2000
Accelerating the return to work (RTW) chances of coronary heart disease (CHD) patients: part 1--development and validation of a training programme
A Mital, D E Shrey, M Govindaraju, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography
|
November 1, 1989
Regional wall motion index for infarct and noninfarct regions after reperfusion in acute myocardial infarction: comparison with global wall motion index
P D Bourdillon, T M Broderick, S G Sawada, et al.
The American Journal of Cardiology
|
March 15, 1989
Early recovery of regional left ventricular function after reperfusion in acute myocardial infarction assessed by serial two-dimensional echocardiography
P D Bourdillon, T M Broderick, E S Williams, et al.
Journal of Thrombosis and Thrombolysis
|
June 22, 1999
Efficacy of abciximab induced platelet blockade using a rapid point of care assay
D J Kereiakes, M Mueller, W Howard, et al.
The American Journal of Cardiology
|
August 3, 2000
Usefulness of stent length in predicting in-stent restenosis (the MULTI-LINK stent trials)
D Kereiakes, T J Linnemeier, D S Baim, et al.
The American Journal of Cardiology
|
September 1, 1999
Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
D J Kereiakes, T M Broderick, E M Roth, et al.
Circulation
|
August 19, 1997
Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment
D J Kereiakes, N Kleiman, J J Ferguson, et al.
Journal of Thrombosis and Thrombolysis
|
December 30, 1999
High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists
D J Kereiakes, T M Broderick, E M Roth, et al.
American Heart Journal
|
March 7, 2001
Dalteparin in combination with abciximab during percutaneous coronary intervention
D J Kereiakes, N S Kleiman, E Fry, et al.
The Journal of Invasive Cardiology
|
April 14, 2000
Combination enoxaparin-abciximab therapy during coronary intervention: the next standard of care?
D A Tramuta, D J Kereiakes, E J Dippel, et al.
Page
of 3